Table 1 Baseline characteristics of patients in COVID-19 phase and pre-COVID-19 phase
Clinical characteristic | Pre-COVID phase | COVID phase | p value |
|---|---|---|---|
Patient (n) | 614 | 600 | |
Age (in years) + SD | 55.27 ± 17.09 | 56.97 ± 15.09 | 0.56 |
Sex (M/F) | 402/212 | 378/222 | 0.37 |
Rural (n, %) | 387 (63.03) | 398 (66.34) | 0.23 |
Urban (n, %) | 227 (36.97) | 202 (33.67) | |
HTN (n, %) | 238 (38.76) | 218 (36.33) | 0.40 |
Diabetes (n, %) | 213 (34.6) | 189 (31.5) | 0.24 |
CKD (n,%) | 73 (11.88) | 54 (9) | 0.11 |
CAD (n, %) | 205 (33.38) | 189 (31.5) | 0.50 |
Indication of OAC | |||
Atrial fibrillation (n, %) | 156 (25.4) | 174 (29) | 0.17 |
Prosthetic valve (n, %) | 254 (41.3) | 232 (38.7) | 0.34 |
Pulmonary thromboembolism (n, %) | 117 (19.1) | 101 (16.9) | 0.33 |
Other (n, %) | 87 (14.16) | 93 (15.5) | 0.46 |
Drugs | |||
OAC (n, %) | 525 (86.6) | 506 (84.4) | 0.57 |
NOAC (n, %) | 89 (14.4) | 94 (15.6) | 0.57 |
Antiplatelets (n, %) | 267 (43.48) | 218 (36.33) | 0.01 |